Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline –– Industry ...
Robert Brooks will outline the clinical progress, commercial potential and global development strategy for Radiance’s lead asset, RB-601 — the first in class bispecific nano ADC engineered to ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced first-patient-in for a Phase 1 clinical ...
ArriVent Biopharma, a company that secures rights to drugs from emerging markets to develop them for Western markets, is adding to its pipeline with a Phase 1-ready drug candidate from China that has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results